SCYNEXIS INC
SCYX · XNASCIK 1178253fmd_1B47GEJ19SV3341MY25NEY0PZ9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 55 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 13 | 5 | 140 | 4 | 21 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 20 | 18 | 22 | 38 | 37 | 24 | 27 | 31 | 26 | 22 |
| Selling, general and administrative | 8 | 8 | 9 | 11 | 15 | 50 | 63 | 21 | 14 | 14 |
| Total operating expenses | 28 | 27 | 30 | 49 | 51 | 74 | 91 | 67 | 41 | 37 |
| Operating income | (28) | (26) | (30) | (49) | (51) | (61) | (86) | 73 | (37) | (16) |
| Interest expense | 0 | 1 | 2 | 1 | 1 | 3 | 5 | 3 | 1 | 0 |
| Other non-operating income (expense) | (2) | 1 | 11 | (5) | (7) | 25 | 18 | (5) | 16 | 7 |
| Income before taxes | (30) | (25) | (19) | (54) | (58) | (36) | (68) | 67 | (21) | (9) |
| Income tax expense | 0 | 0 | (7) | 0 | (3) | (3) | (5) | 0 | 0 | 0 |
| Net income from continuing operations | (30) | (25) | (12) | (54) | (55) | (33) | (63) | 67 | (21) | (9) |
| Net income | (30) | (25) | (12) | (54) | (55) | (33) | (63) | 67 | (21) | (9) |
| Net income to common shareholders | (30) | – | – | – | – | – | (63) | 67 | (21) | – |